Last checked at 19 May 2017 14:44
Hikma Pharmaceuticals PLC
Voting Results of 2017 Annual General Meeting
LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 19 were passed as ordinary resolutions and Resolutions 20 to 23 were passed as special resolutions.
As previously announced, Mr. Michael Ashton retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2017) is set out below. The number of Ordinary Shares in issue on 19 May 2017 was 240,380,475.
Resolution | Votes For | % | Votes Against | % | Withheld | Total Cast |
1. To receive the 2016 report and accounts | 197,423,759 | 99.84% | 319,920 | 0.16% | 6,643 | 197,750,322 |
2. To approve a final dividend of 22 cents per share | 197,743,879 | 100.00% | 0 | 0.00% | 6,443 | 197,750,322 |
3. To re-appoint PricewaterhouseCoopers LLP as auditors | 197,741,251 | 100.00% | 905 | 0.00% | 8,166 | 197,750,322 |
4.To authorise the Audit Committee to determine the auditors' remuneration | 197,688,953 | 99.97% | 53,203 | 0.03% | 8,166 | 197,750,322 |
5. To elect Nina Henderson as a director | 197,534,627 | 99.89% | 208,786 | 0.11% | 6,854 | 197,750,267 |
6. To re-elect Said Darwazah as a director | 193,519,353 | 98.05% | 3,848,526 | 1.95% | 382,442 | 197,750,321 |
7. To re-elect Mazen Darwazah as a director | 195,813,592 | 99.21% | 1,551,895 | 0.79% | 384,835 | 197,750,322 |
8. To re-elect Robert Pickering as a director | 197,076,319 | 99.66% | 667,559 | 0.34% | 6,443 | 197,750,321 |
9.To re-elect Ali Al-Husry as a director | 196,769,085 | 99.57% | 857,947 | 0.43% | 123,290 | 197,750,322 |
10. To re-elect Dr. Ronald Goode as a director | 195,703,815 | 98.97% | 2,039,923 | 1.03% | 6,584 | 197,750,322 |
11. To re-elect Patrick Butler as a director | 197,506,890 | 99.88% | 236,848 | 0.12% | 6,584 | 197,750,322 |
12. To re-elect Dr. Jochen Gann as a director | 196,795,912 | 99.58% | 830,979 | 0.42% | 123,431 | 197,750,322 |
13. To re-elect John Castellani as a director | 197,586,602 | 99.92% | 157,277 | 0.08% | 6,443 | 197,750,322 |
14. To re-elect Dr. Pamela Kirby as a director | 195,665,777 | 98.96% | 2,053,602 | 1.04% | 6,468 | 197,725,847 |
15. To approve the directors' remuneration policy | 169,053,856 | 86.39% | 26,622,257 | 13.61% | 2,074,207 | 197,750,320 |
16. To approve the remuneration report for the year ended 31 December 2016 | 193,651,599 | 97.93% | 4,091,754 | 2.07% | 6,968 | 197,750,321 |
17. To approve the extension of the effective period of the Executive Incentive Plan | 170,276,525 | 86.12% | 27,450,966 | 13.88% | 22,830 | 197,750,321 |
18. To approve the increase of the aggregate directors' fee limit | 197,640,307 | 99.98% | 45,091 | 0.02% | 64,924 | 197,750,322 |
19. Authority to allot shares | 170,146,304 | 86.21% | 27,221,034 | 13.79% | 382,984 | 197,750,322 |
20. To dis-apply pre-emption rights for general purposes | 196,872,145 | 99.56% | 869,023 | 0.44% | 9,154 | 197,750,322 |
21. To dis-apply pre-emption rights for an acquisition or other capital investment | 173,591,716 | 87.79% | 24,149,939 | 12.21% | 8,666 | 197,750,321 |
22. To authorise the Company to purchase its own shares | 197,014,413 | 99.66% | 676,265 | 0.34% | 59,643 | 197,750,321 |
23. To authorise the Company to hold general meetings on no less than 14 clear days' notice | 187,053,655 | 94.82% | 10,213,802 | 5.18% | 482,864 | 197,750,321 |
Declaration of final dividend
The dividend of 22 cents per share will be paid on 25 May 2017 to shareholders on the register on 7 April 2017. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2898 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
Susan Ringdal VP for Investor Relations and Strategy
| +44 20 7399 2670
|
About Hikma
Hikma Pharmaceuticals PLC is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2016, Hikma achieved revenue of $1,950 million and profit attributable to shareholders of $155 million. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee. For more information visit www.hikma.com.